Novo Nordisk Reports New CagriSema Results Across REDEFINE Trials

Share on Social Media

Novo Nordisk CagriSema clinical trial findings showing lower-dose weight loss results in REDEFINE 9 and response outcomes in REDEFINE 1.

Novo Nordisk reports approximately 21% weight loss with lower-dose CagriSema in REDEFINE 9, alongside new response and quality-of-life findings from REDEFINE 1.

Written By: Kirti Kumbhar, M. Pharm (QA)

Reviewed By: Pharmacally Editorial Team

Novo Nordisk presented additional Phase 3 evidence for investigational CagriSema at ObesityWeek 2026, including lower-dose efficacy results from REDEFINE 9 and two post hoc analyses of REDEFINE 1. The findings expand the clinical evidence for the once-weekly combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, across weight reduction, treatment response, and patient-reported outcomes.

REDEFINE 9: Lower Doses Achieved Approximately 21% Estimated Weight Loss

REDEFINE 9 was a 68-week, randomized, double-blind, placebo-controlled Phase 3b study involving 309 adults with obesity or overweight and at least one obesity-related complication, without diabetes. Participants received CagriSema 1.7 mg/1.7 mg or 1.0 mg/1.0 mg, or corresponding placebo regimens, alongside lifestyle intervention.

The trial evaluated two co-primary endpoints: percentage change in body weight and the proportion of participants achieving at least 5% weight loss at Week 68.

Under the efficacy estimand, mean body-weight reduction reached 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with CagriSema 1.0 mg/1.0 mg, compared with 2.0% with placebo. At least 5% weight loss was achieved by 95.1% (1.7 mg/1.7 mg) and 96.3% (1.0 mg/1.0 mg) of participants, versus 33.4% with placebo. More than half of participants in both CagriSema groups achieved at least 20% weight loss. Waist circumference decreased by 17.2 cm with the 1.7 mg/1.7 mg dose and 17.5 cm with the 1.0 mg/1.0 mg dose, compared with 3.6 cm with placebo.

When treatment discontinuation and use of weight-management rescue interventions were accounted for under the treatment-regimen estimand, mean weight reduction was 19.4% with CagriSema 1.7 mg/1.7 mg and 18.6% with CagriSema 1.0 mg/1.0 mg, versus 4.6% with placebo.

These two estimands provide complementary perspectives: the efficacy estimand estimates the treatment effect assuming adherence, whereas the treatment-regimen estimand incorporates treatment discontinuation and rescue intervention. Because the study was not powered to establish differences between the two CagriSema doses, the numerically similar results do not demonstrate dose equivalence or superiority of the lower dose.

REDEFINE 1: Post Hoc Analyses Examine Response Patterns and Functional Outcomes

Novo Nordisk also reported two post hoc analyses from REDEFINE 1, a 68-week, Phase 3, placebo- and active-controlled trial involving 3,417 adults with obesity or overweight and comorbidities, without type 2 diabetes. The analyses evaluated the higher CagriSema 2.4 mg/2.4 mg regimen.

Early Versus Delayed Weight-Loss Response

Participants achieving at least 5% weight loss by Week 8 were classified as early responders, while those below this threshold were classified as delayed responders. Among 2,016 participants included in the on-treatment analysis, 67.8% (n = 1,367) were early responders.

At Week 68, observed mean weight loss was 25.4% among early responders compared with 17.8% among delayed responders. At least 20% weight loss was achieved by 73.3% and 37.2% of participants, respectively. Women were more likely to be early responders than delayed responders (71.8% versus 59.5%), according to the company-reported analysis.

These findings are hypothesis-generating and based on observed on-treatment data. They do not establish early weight loss as a validated predictor of individual long-term treatment response.

Patient-Reported Physical and Psychosocial Function

A separate post hoc analysis used the validated Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) questionnaire. At Week 68, meaningful within-person improvement in physical function was reported by 73.1% of CagriSema recipients compared with 49.1% receiving placebo. Improvements in psychosocial function were reported by 69.0% versus 42.1%, while total scores improved meaningfully in 69.1% versus 40.4%.

The analysis used predefined meaningful-change thresholds of 14.6 points for physical function, 16.2 points for psychosocial function, and 16.6 points for total score (with a 13.5-point threshold also established for the overall physical domain). Physical-function improvement was significantly greater with CagriSema from Week 8 through Week 68.

These results extend the assessment beyond body-weight reduction to patient-reported functional and psychosocial outcomes. However, they remain post hoc findings rather than independently established confirmatory endpoints.

Safety and Regulatory Status

In REDEFINE 9, gastrointestinal events were the most frequently reported adverse events and were generally mild to moderate. Permanent discontinuation due to adverse events occurred in 2.9% of participants receiving CagriSema 1.7 mg/1.7 mg and 4.9% receiving CagriSema 1.0 mg/1.0 mg, compared with 4.9% with placebo.

In REDEFINE 1, gastrointestinal adverse events occurred in 79.6% of CagriSema recipients versus 39.9% with placebo, with nausea, constipation, and vomiting most frequently reported. Discontinuation due to adverse events occurred in 5.9% and 3.5% of participants, respectively.

Novo Nordisk submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in December 2025 for CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026, according to the company. CagriSema remains investigational and is not approved for this use in the United States.

Clinical Interpretation

REDEFINE 9 provides evidence that substantial weight reduction was achieved with both evaluated lower-dose regimens, although the absence of a powered dose comparison prevents conclusions about equivalence. The REDEFINE 1 analysis add insights into individual weight-loss trajectories and patient-reported functional improvements, though their post hoc nature limits their role in guiding clinical treatment decisions. Together, the findings broaden the clinical evidence for CagriSema while leaving questions about optimal dose selection, response prediction, and confirmatory patient-reported outcomes for further evaluation.

Reference

Novo’s CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026, Novo Nordisk, 15 November 2026

Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology, Novo Nordisk, 14 November 2026

A Research Study to See How Well CagriSema Helps People with Excess Body Weight Lose Weight (REDEFINE 1), ClinicalTrials.gov ID NCT05567796

A Research Study to See How Well Different Doses of CagriSema Help People with Excess Body Weight Lose Weight, ClinicalTrials.gov ID NCT06388187

About the Writer

Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.


Share on Social Media
Scroll to Top